Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Secretory leukocyte protease inhibitor in ovarian endometriomas following GnRH agonist therapy
Autore:
Suzumori, N; Sato, M; Ikuta, K; Suzumori, K;
Indirizzi:
Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 , Dept Pathol, Houston, TX 77030 USA Fukui Med Univ, Dept Anat 2, Fukui, Japan Fukui Med Univ Fukui JapanFukui Med Univ, Dept Anat 2, Fukui, Japan Nagoya City Univ, Sch Med, Dept Obstet & Gynecol, Nagoya, Aichi 467, JapanNagoya City Univ Nagoya Aichi Japan 467 Gynecol, Nagoya, Aichi 467, Japan
Titolo Testata:
OBSTETRICS AND GYNECOLOGY
fascicolo: 4, volume: 97, anno: 2001,
pagine: 561 - 566
SICI:
0029-7844(200104)97:4<561:SLPIIO>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
MENSTRUAL-CYCLE; CERVICAL-MUCUS; WOMEN; EXPRESSION; ELASTASE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Suzumori, N Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA Baylor Coll Med 1 Baylor Plaza Houston TX USA 77030 77030 USA
Citazione:
N. Suzumori et al., "Secretory leukocyte protease inhibitor in ovarian endometriomas following GnRH agonist therapy", OBSTET GYN, 97(4), 2001, pp. 561-566

Abstract

Objective: To determine whether expression of secretory leukocyte proteaseinhibitor is affected in tissue and peritoneal fluid of women with ovarianendometriomas treated with GnRH analogues. Methods: In 32 women with endometriomas (17 untreated and 15 treated with GnRH analogue) and 21 with ovarian cystadenomas, we examined the expressionof secretory leukocyte protease inhibitor messenger RNA (mRNA) by Northernblot analysis; protein distribution was measured immunohistochemically. Concentrations of secretory leukocyte protease inhibitor in peritoneal fluid were measured by enzyme-linked immunosorbent assay. Expression of secretoryleukocyte protease inhibitor in endometrioma explants in vitro was also studied with and without the GnRH analogue treatment. Results: Secretory leukocyte protease inhibitor mRNA expression was identified only in untreated endometriomas. In the GnRH agonist-treated endometriomas, the semiquantitative H-score for secretory leukocyte protease inhibitor immunostaining was significantly lower than that for untreated endometriomas (P < .001). The peritoneal fluid of the GnRH agonist-treated women also contained significantly lower concentrations of secretory leukocyte protease inhibitor (median 76 ng/mL, interquartile range 51-131 ng/mL; P < .001)than untreated women (124 ng/mL, 70-186 ng/mL). Secretory leukocyte protease inhibitor in endometrioma explants in vitro was significantly inhibited by the GnRH analogue (P < .05). Conclusion: Expression of secretory leukocyte protease inhibitor in tissueand peritoneal fluid of women with ovarian endometriomas was decreased by GnRH agonist treatment. <(c)> 2001 by The American College of Obstetriciansand Gynecologists.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 04:39:12